The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

XTalks

OCTOBER 21, 2020

Related: Study Dispels Claim that COVID-19-Causing Coronavirus is Lab-Engineered. In addition, Berrio and colleagues discovered other novel targets of positive selection, namely within genes encoding Nsp4 and Nsp16, which are viral enterotoxins important for the stability of the RNA structure of the virus.

RNA 98

RNA Protein Genome Genomics 98

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc.,

Vaccination 52

Vaccination Vaccine Marketing RNA 52

Pfizer

DECEMBER 13, 2021

Shot of a Lifetime: How Two Pfizer Manufacturing Plants Upscaled to Produce the COVID-19 Vaccine in Record Time. Shot of a Lifetime: How Two Pfizer Manufacturing Plants Upscaled to Produce the COVID-19 Vaccine in Record Time. Anonymous (not verified). Mon, 12/13/2021 - 11:40. But there was no time for debate.

Manufacturing 52

Manufacturing Vaccination Vaccine Production 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. “This is just the beginning; the potential is enormous,” he says. About Whitelab Genomics.

Genome 105

Genome Genomics Medicine Development 105

XTalks

OCTOBER 8, 2024

In a statement , the Nobel Assembly said the laureates discovered a new class of non-coding RNA molecules that play a crucial role in gene regulation. To activate these instructions, cells create a copy called messenger RNA (mRNA), which exits the nucleus and directs the cell’s machinery to produce a specific protein.

Regulation 52

Regulation Genetics Scientist RNA 52

Pharmaceutical Technology

DECEMBER 15, 2022

The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.

Manufacturing 264

Manufacturing Vaccination Vaccine Production 264

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. percent in the placebo group.

FDA Approval 112

FDA Approval Gene Therapy Clinical Trials Gene 112

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery.

RNA 52

RNA Drug Delivery Engineer Gene Therapy 52

XTalks

MARCH 8, 2022

From leading COVID-19 vaccine developments to being at the helm of the latest gene therapies and inventing ground-breaking DNA technologies like CRISPR, women have been at the forefront of some of the most leading-edge scientific discoveries in recent years, both as innovators and leaders.

Life Science 106

Life Science Gene Therapy DNA Vaccination 106

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

XTalks

JUNE 18, 2024

In a field quickly gaining attention for its role in vaccine development and personalized medicine, Elixirgen Therapeutics stands out through its pursuit of innovation and safety. Founded in Baltimore, Maryland, a vibrant science hub, Elixirgen Therapeutics emerged from a vision to harness the untapped potential of mRNA technology.

Protein 52

Protein RNA Genetics Gene Expression 52

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

NOVEMBER 1, 2021

The project, detailed in an open-access paper in Computers in Biology and Medicine, incorporates models of three drug targets – main protease (Mpro), RNA-dependent RNA polymerase (RdRp) and Papain-like protease (PLpro) – for ensemble docking through DINC-COVID. Lydia Kavraki, a computer scientist at the George R.

Drugs 52

Drugs Protein Engineer RNA 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Roots Analysis

FEBRUARY 13, 2023

With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

DECEMBER 8, 2020

Curexsys is founded by Herbert Stadler, a serial biotech entrepreneur, and Jens Gruber, a former group leader of Medical RNA Biology who is going to lead Curexsys as Chief Scientific Officer. These efforts have been held back by a dearth of standardised methods to isolate and study vesicles.

Manufacturing 52

Manufacturing Containment Life Science Production 52

The Pharma Data

OCTOBER 27, 2020

As part of those efforts, it has become increasingly clear that to tackle the pandemic at a global level the development of medicines that can prevent and treat the virus, in addition to the development of vaccines, will be crucial. These building blocks are designed to target different sites on the virus for multiple concurrent effects.

Development 40

Development Protein Manufacturing Medicine 40

The Pharma Data

MARCH 4, 2021

We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. For more information on Ovid, please visit www.ovidrx.com. .

Development 52

Development Containment Medicine Clinical Trials 52

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc. and OriCiro Genomics K.K.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. When treatments involve recombinant or synthetic nucleic acids, including messenger RNA (mRNA) or viral vector vaccines, additional IBC oversight is necessary.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

The Pharma Data

JANUARY 10, 2021

Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. China’s Sinovac Biotech reported that its COVID-19 vaccine, CoronaVac, had a 78% efficacy rate in a Phase III clinical trial in Brazil. The drug is an RNA interference (RNAi) therapeutic. Here’s a look.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

AUGUST 23, 2024

Vaccinations in the past have always been either weak or inactive forms of a pathogen which was given to the body so that our immune system is trained to recognize that given pathogen. There are several advantages to approaching vaccination this way. This alone makes them much safer than most conventional vaccines on the market today.

Protein 40

Protein Vaccination Vaccine Immune Response 40

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. The currently approved CD-19 CAR products are autologous, ex vivo cellular therapies.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

The Pharma Data

DECEMBER 27, 2020

Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. CureVac and the University Medical Center of Mainz launched a Phase III trial of CVnCoV, their COVID-19 vaccine candidate, in healthcare workers. platforms and the human GM-CSF cytokine.

Trials 52

Trials Antibody Gene Therapy Gene 52

Roots Analysis

MAY 21, 2024

Gene Therapies: LNPs have the ability to effectively deliver nucleic acids, including small interfering RNA (siRNA), messenger RNA (mRNA), and plasmid DNA to the target cells. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

JANUARY 6, 2025

From leveraging artificial intelligence (AI) to streamline diagnostics and treatments to exploring the untapped potential of RNA-based therapeutics, biotechnology is shaping the future of healthcare and beyond. As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

The Pharma Data

JANUARY 7, 2021

The implications for vaccines are less clear in the long run because the virus will continue to mutate, though the consensus is that the new coronavirus vaccines will likely still work because they trigger the creation of a broad array of neutralizing antibodies and other immune system responses. But the U.S. In response, Gov.

Vaccination 52

Vaccination Vaccine Antibody RNA 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92